Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02208362 : Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
PhasePhase 1
AgesMin: 12 Years Max: 75 Years
Inclusion Criteria:


- Participant has a prior histologically-confirmed diagnosis of a grade III or IV
glioma, or has a prior histologically-confirmed diagnosis of a grade II glioma and now
has radiographic progression consistent with a grade III or IV malignant glioma (MG)
after completing standard therapy

- Radiographic evidence of progression/recurrence of the measurable disease more than 12
weeks after the end of the initial radiation therapy

- Karnofsky performance status (KPS) >= 60%

- Life expectancy > 4 weeks

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control or abstinence) prior to study entry and
for six months following duration of study participation; should a woman become
pregnant or suspect that she is pregnant while participating on the trial, she should
inform her treating physician immediately

- COH Clinical Pathology confirms IL13R alpha 2+ tumor expression by
immunohistochemistry (>= 20%, 1+)

- All research participants must have the ability to understand and the willingness to
sign a written informed consent


- Research participant must not require more than 2 mg TID of Dexamethasone on the day
of PBMC collection

- Research participant must have appropriate venous access

- At least 2 weeks must have elapsed since the research participant received his/her
last dose of prior chemotherapy or radiation


- Creatinine < 1.6 mg/dL

- White blood cell (WBC) > 2,000/dl

- Absolute neutrophil count (ANC) > 1,000

- Platelets >= 100,000/dl

- International normalized ratio (INR) < 1.3

- Bilirubin < 1.5 mg/dL

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper
limits of normal

- An interval of at least 12 weeks must have elapsed since the completion of initial
radiation therapy

- At least 6 weeks since the completion of a nitrosourea-containing chemotherapy regimen

- At least 23 days since the completion of Temodar and/or 4 weeks for any other
non-nitrosourea-containing cytotoxic chemotherapy regimen; if a patient's most recent
treatment was with a targeted agent only, and s/he has recovered from any toxicity of
this targeted agent, then a waiting period of only 2 weeks is needed from the last
dose and the start of study treatment, with the exception of bevacizumab where a wash
out period of at least 4 weeks is required before starting study treatment


- Research participant has a released cryopreserved T cell product

- Research participant does not require supplemental oxygen to keep saturation greater
than 95% and/or does not have presence of any radiographic abnormalities on chest
x-ray that are progressive

- Research participant does not require pressor support and/or does not have symptomatic
cardiac arrhythmias

- Research participant does not have a fever exceeding 38.5° Celsius (C); there is an
absence of positive blood cultures for bacteria, fungus, or virus within 48-hours
prior to T cell infusion and/or there aren't any indications of meningitis

- Serum total bilirubin does not exceed 2 x normal limit

- Transaminases does not exceed 2 x normal limit

- Serum creatinine =< 1.8 mg/dL

- Research participant does not have uncontrolled seizure activity following surgery
prior to starting the first T cell dose

- Platelet count must be >= 100,000; however, if platelet level is between
75,000-99,000, then T-cell infusion may proceed after platelet transfusion is given
and the post transfusion platelet count is >= 100,000

- Research participants must not require more than 2 mg thrice daily (TID) of
dexamethasone during T cell therapy

Exclusion Criteria:


- Research participant requires supplemental oxygen to keep saturation greater than 95%
and the situation is not expected to resolve within 2 weeks

- Research participant requires pressor support and/or has symptomatic cardiac

- Research participant requires dialysis

- Research participant has uncontrolled seizure activity and/or clinically evident
progressive encephalopathy

- Failure of research participant to understand the basic elements of the protocol
and/or the risks/benefits of participating in this phase I study; a legal guardian may
substitute for the research participant

- Research participants with any non-malignant intercurrent illness which is either
poorly controlled with currently available treatment, or which is of such severity
that the investigators deem it unwise to enter the research participant on protocol
shall be ineligible

- Research participants with any other active malignancies

- Research participants being treated for severe infection or who are recovering from
major surgery are ineligible until recovery is deemed complete by the investigator

- Research participants with any uncontrolled illness including ongoing or active
infection; research participants with known active hepatitis B or C infection;
research participants with any signs or symptoms of active infection, positive blood
cultures or radiological evidence of infections

- Research participants who have confirmed HIV positivity within 4 weeks of screening

- Subjects, who in the opinion of the investigator, may not be able to comply with the
safety monitoring requirements of the study
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557